Command Palette

Search for a command to run...

Clinical Trials · NCT01638260

GLP-1 and Non-exercise Activity Thermogenesis in RHZ

TerminatedPhase 4Liraglutide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
Maastricht University Medical Center
Enrollment
22
Start date
Oct 2012
Locations
1 site, Netherlands
Primary endpoint
Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)
View Liraglutide compound reference